Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) have been assigned a consensus rating of “Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $19.33.

Several analysts have recently issued reports on ADAP shares. ValuEngine upgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Cowen reiterated a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Wednesday, August 15th. BidaskClub upgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, June 18th. Guggenheim started coverage on shares of Adaptimmune Therapeutics in a research note on Monday, September 17th. They issued a “buy” rating for the company. Finally, TheStreet lowered shares of Adaptimmune Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, July 16th.

NASDAQ ADAP opened at $11.89 on Friday. Adaptimmune Therapeutics has a 1 year low of $6.60 and a 1 year high of $14.63. The firm has a market capitalization of $1.11 billion, a PE ratio of -14.86 and a beta of 1.09.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.20). Adaptimmune Therapeutics had a negative return on equity of 47.22% and a negative net margin of 191.14%. The firm had revenue of $9.04 million during the quarter, compared to the consensus estimate of $7.76 million. research analysts expect that Adaptimmune Therapeutics will post -1.02 earnings per share for the current year.

In related news, Director Ali Behbahani purchased 12,000,000 shares of Adaptimmune Therapeutics stock in a transaction that occurred on Friday, September 7th. The stock was bought at an average price of $1.67 per share, for a total transaction of $20,040,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Enterprise Associates 14 New purchased 3,000,000 shares of Adaptimmune Therapeutics stock in a transaction that occurred on Friday, September 7th. The shares were bought at an average price of $1.67 per share, with a total value of $5,010,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of ADAP. BNP Paribas Arbitrage SA bought a new position in Adaptimmune Therapeutics during the second quarter valued at about $122,000. BB&T Securities LLC purchased a new stake in Adaptimmune Therapeutics during the second quarter valued at about $128,000. Jane Street Group LLC purchased a new stake in Adaptimmune Therapeutics during the first quarter valued at about $168,000. Trexquant Investment LP purchased a new stake in Adaptimmune Therapeutics during the second quarter valued at about $178,000. Finally, Trellus Management Company LLC purchased a new stake in Adaptimmune Therapeutics during the second quarter valued at about $195,000. Institutional investors own 59.32% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

See Also: How can investors find ex-dividend dates?

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.